Celgene fends off Kyle Bass challenge
Feng Yu / Shutterstock.com
The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board (PTAB) to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
USPTO; PTAB; Celgene; patents; Coalition for Affordable Drugs; Kyle Bass;